Washington, D.C.—Last month WholeFoods reported that the U.S. Food and Drug Administration (FDA) was giving signs it would approve the introduction of a genetically modified salmon product. Eleven senators from mostly coastal states have since tried to halt the approval process, urging FDA to consider the matter more closely before making a decision.
Pomegranate product makers POM Wonderful are embroiled in a fight with the U.S. Federal Trade Commission (FTC) over their use of health claims-based marketing for their products. The action is the latest example of efforts by FTC and the U.S. Food and Drug Administration (FDA) to more heavily scrutinize and regulate health claims from product manufacturers.
A ruling by the Sixth Circuit of the United States Court of Appeals has overturned an existing Ohio ban on milk labels carrying a hormone-free claim. Now, dairy products not produced from cows raised on rBGH (recombinant Bovine Growth Hormone) can say so on the package.
Las Vegas, NV—More than 1,200 exhibit booths (with 779 total companies) and a packed educational session drew 8,500 industry members to this year’s SupplySide West tradeshow and convention, held here from October 19 to 23.
Hoboken, NJ—New research published in the Journal of the Science of Food and Agriculture indicates there may be a new application for a well-known branded extract of the French maritime pine tree bark (Pycnogenol from Natural Health Sciences, based here).
The Federal Trade Commission (FTC) has been mighty busy lately. WholeFoods reports in this issue about their legal square-offs against companies like POM Wonderful over contentious marketing claims. The agency is also finding time to set its sights on all the “greenwashers” out there in marketing land. “Greenwashing” is a term some use to describe marketing efforts that exploit the eco-friendly trend, even when the product being marketed may not be so eco-friendly.
Washington, D.C.— Following negotiations with law firm Emord & Associates, FDA will now allow select cancer-related health claims on selenium supplement product labels. The U.S. District Court for the District of Columbia overruled FDA’s decision to censor four qualified health claims, by finding it in violation of the First Amendment commercial speech standard.